Efficacy and Tolerability of Low-dose Transdermal Estrogen (Oesclim®) in the Treatment of Menopausal Symptoms
| Autor: | H. Chadha-Boreham, A. Cyganek, L. Marianowski, Y. Leocmach, E. Barcz, H. Gadomska |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
Adult
medicine.medical_specialty medicine.drug_class medicine.medical_treatment Administration Oral Sweating Administration Cutaneous Transdermal estrogen Internal medicine Flushing Humans Medicine Prospective Studies Progesterone Transdermal Chemotherapy Estradiol Progestogen business.industry Low dose Drug Tolerance General Medicine Middle Aged Patient Acceptance of Health Care medicine.disease Surgery Menopause Tolerability Estrogen Female Safety business |
| Zdroj: | Current Medical Research and Opinion. 18:97-102 |
| ISSN: | 1473-4877 0300-7995 |
| DOI: | 10.1185/030079902125000291 |
| Popis: | To establish the proportion of symptomatic postmenopausal women who can be satisfactorily maintained on a low HRT dose of 25 microg/day 17-beta-estradiol (Oesclim 25 transdermal patches), after 8 weeks of treatment.This was a multicenter open label non-comparative trial. Treatment was initiated with 25 microg/day dosage, which could be increased to 50pg/day if required after 8 weeks, according to clinical evaluation. Sequential treatment with an oral progestogen was also given foror = 12 days/month in all non-hysterectomized women. The primary criterion for evaluation of efficacy was the proportion of patients who remained on Oesclim 25 after 8 weeks of treatment in comparison to patients requiring Oesclim 50.Sixty-two patients were included in the study and 60 were treated. 88.3% of treated patients [CI: 78.7-94.9] fulfilled the primary criterion, remaining with the Oesclim 25 dosage after 8 weeks of treatment. All clinical menopausal symptoms showed a decrease from baseline to the end of the study. The mean daily number of vasomotor symptoms decreased from 8.2 (+/- 5.6) at baseline, for the entire treated population, to 1.0 (+/- 2.2) and 1.0 (+/- 1.2) at the end of the study in patients remaining with Oesclim 25 and in those requiring Oesclim 50, respectively. At the interim visit, patients in the Oesclim 50 group had a higher number of symptoms than those maintained on Oesclim 25. The global efficacy of the treatment was evaluated as very effective/effective by 93% of all patients and very good/good by investigators for 91% of their patients. Overall 91% of all patients evaluated the global tolerability as very well/well, while investigators rated it very good/good for 97% of their patients. The vast majority of all patients (93%) were very satisfied/satisfied with the trial treatment, and 90% of them were willing to continue the study drug.Oesclim low dose (25microg) hormonal transdermal therapy was efficient in management of climacteric symptoms in this 16-week study. The good acceptance of the treatment was associated with its high efficiency and tolerability. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|